Drug Trial Radar · NCT01297452
BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Mar 31, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
Feb 15, 2011
Primary completion
Mar 29, 2017
Study completion Mar 29, 2017
Sponsor
- Lead sponsor
- Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Novartis Pharmaceuticals; Sai Life Sciences
- First posted
- Feb 16, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to find out the good and bad effects that occur when BKM120 is added to standard chemotherapy with carboplatin and paclitaxel.
Conditions
- Solid Tumors
Interventions
BKM120 days 1 - 21 plus paclitaxel + carboplatinDrug
Patients will receive oral daily BKM120 (days 1 - 21, per dose escalation scheme) plus paclitaxel (175 mg/m2 intravenously, day 1) + carboplatin (AUC 5 intravenously, day 1)on a 21-day cycle. Pegfilgrastim (6 mg/subcutaneously) will be administered on day 2 of each cycle.
BKM120 (days 1 - 28, ) plus paclitaxel + carboplatinDrug
Patients will receive oral daily BKM120 (days 1 - 28, per dose escalation scheme) plus paclitaxel (80 mg/m2 intravenously, days 1, 8 and 15) + carboplatin (AUC 5 intravenously, day 1) on a 28-day cycle.
BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1)Drug
BKM120 100 mg (days 1 - 21, per dose escalation scheme) plus paclitaxel (200 mg/m2 intravenously, day 1) + carboplatin (AUC 6 intravenously, day 1) on a 21-day cycle. After enrollment to Groups 1 and 2 has been completed and all patients in Group 1 and 2 have completed the DLT monitoring period, up to 6 additional patients will be enrolled in this EXPANSION COHORT.A
BKM120, Paclitaxel + CarboplatinDrug
BKM120 100 mg per oral, days 1 - 21 Paclitaxel (175 mg/m2) intravenously on Day 1 Carboplatin (AUC 5) intravenously on Day 1 EXPANSION COHORT B
Primary outcomes
What the sponsor says the trial is designed to measure.
- To establish the phase II recommended dose of daily oral BKM120Time frame: 2 years
- EXPANSION COHORT A:To evaluate the safety and tolerability of daily oral BKM120 (100 mg) + paclitaxel (200 mg/m2) + carboplatin (AUC 6), both given intravenously (IV) on day 1 of a 21-day cycle, with pegfilgrastim supportTime frame: 2 years
- EXPANSION COHORT B: To obtain a preliminary description of efficacy of the regimen established in Group 1 among patients with tumors harboring PTEN mutation or homozygous deletion.Time frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Memorial Sloan Kettering Cancer Center
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.